Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00141323 · ClinicalTrials.gov registry record · Phase 3
Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)
A Phase 3 study, sponsored by Ligand Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,556
- Enrollment target
NCT00141323 is a Phase 3 study that has completed, run by Ligand Pharmaceuticals. The registered enrollment target is 8,556 participants.
The verdict
NCT00141323, a Phase 3 study, has completed, sponsored by Ligand Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,556 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety and effectiveness of 2 doses of the investigational drug, lasofoxifene, compared to placebo (an inactive substance) in reducing new spinal fractures in women with osteoporosis.
Interventions
- OTHER placebo
- DRUG lasofoxifene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,556 participants |
| Start Date | 2001-11 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00141323
The ClinicalTrials.gov registry entry for NCT00141323 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 8,556 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ligand Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00141323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00141323 about?
NCT00141323 is a clinical study titled "Postmenopausal Evaluation and Risk-reduction With Lasofoxifene (PEARL)". The purpose of the study is to determine the safety and effectiveness of 2 doses of the investigational drug, lasofoxifene, compared to placebo (an inactive substance) in reducing new spinal fractures in women with osteoporosis.
What is the current status of trial NCT00141323?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,556 participants. The study started on 2001-11. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00141323?
The interventions under investigation include: placebo (OTHER), lasofoxifene (DRUG).
Who is sponsoring clinical trial NCT00141323?
This trial is sponsored by Ligand Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.